Genetic Testing Market by Product (Consumables & Equipment, Software & Services), Test Type (Carrier Testing, Diagnostic Testing, New Born Screening), Technology, Application, Distribution Channel, End-User - Global Forecast 2025-2032
Description
The Genetic Testing Market was valued at USD 13.55 billion in 2024 and is projected to grow to USD 15.44 billion in 2025, with a CAGR of 14.38%, reaching USD 39.72 billion by 2032.
An authoritative introduction that frames the current genetic testing landscape, clarifies scope, and outlines strategic implications for stakeholders
This executive summary frames the contemporary genetic testing landscape by establishing the scope of analysis, clarifying core thematic drivers, and defining the strategic questions that matter most to stakeholders across healthcare, diagnostics, and life sciences industries.
The introduction situates genetic testing within a convergence of accelerating technological capability and shifting care models, highlighting how advances in sequencing, informatics, and decentralized testing are expanding diagnostic utility. It explains the analytic boundaries used in this study, including product categories, test modalities, technology platforms, clinical and nonclinical applications, distribution approaches, and end-user settings. By articulating these parameters, the section provides readers with a clear foundation for interpreting subsequent insights and for assessing how observed trends translate into operational and investment priorities. Finally, the introduction positions this work as a decision-oriented synthesis: it is designed to clarify implications for clinical adoption, commercialization, and policy engagement rather than to provide purely descriptive exposition.
Identification of transformative shifts reshaping genetic testing including technological advances, consumer behavior, regulatory dynamics, and care delivery models
The genetic testing landscape is undergoing a set of transformative shifts driven by technological maturation, evolving payer and regulatory frameworks, and changing patient expectations about access and control over health data.
On the technology front, improvements in throughput, accuracy, and cost-efficiency for next‑generation sequencing and complementary modalities are enabling broader clinical applications and accelerating translation from research to routine care. At the same time, software-driven interpretation, artificial intelligence, and cloud-based genomic informatics are redefining how results are processed and integrated into clinical workflows. From a regulatory and reimbursement standpoint, authorities and payers increasingly expect clear evidence of clinical utility and value, creating incentives for companies to generate real-world data and to engage early with health systems and payers. Consumer behavior is also shifting: greater health literacy and demand for convenience are expanding interest in at-home and direct-to-consumer testing pathways, while clinicians seek validated, action-oriented results that inform care decisions. Collectively, these shifts are pushing organizations to rethink product design, partnerships, and commercialization strategies, and they are raising the bar for evidence, interoperability, and data governance.
Assessment of cumulative effects stemming from United States tariff actions in 2025 on supply chains, pricing structures, global collaboration, and patient access
Recent tariff actions originating from the United States in 2025 introduce trade-related headwinds that compound existing supply chain fragilities for genetic testing stakeholders, from instrument manufacturers to clinical laboratories and hospital systems.
Tariffs on imported equipment and consumables can raise landed costs, prompting manufacturers and purchasers to reevaluate procurement strategies and inventory planning. As a consequence, laboratories may face compressed margins while also balancing the imperative to maintain uninterrupted testing capacity for patient care. In response, many organizations are accelerating supplier diversification, regional sourcing, and strategic stockpiling to mitigate near-term disruption. Over the medium term, tariffs can incentivize greater regional manufacturing investment and nearshoring of critical components, but such reconfiguration takes time and capital. These trade measures also influence global collaboration on research and development: partners may adjust contractual terms, timing of instrument deployments, and location of clinical studies to manage cost exposure. Importantly, tariff-induced cost increases risk uneven downstream effects on patient access, particularly for lower-income populations and for settings that lack robust procurement leverage. To preserve affordability and continuity of services, stakeholders will need to prioritize bilateral supplier agreements, engage proactively with trade and regulatory authorities, and model multiple scenarios to understand impacts across procurement, pricing, and reimbursement pathways.
Insightful segmentation analysis revealing how product, test type, technology, application, distribution channel, and end-user dynamics inform market positioning
A granular segmentation lens reveals differentiated dynamics across product, test type, technology, application, distribution channel, and end-user dimensions, each carrying distinct strategic implications.
When viewed by product, Consumables & Equipment experience capital expenditure sensitivities and logistics complexity that favor scale and supply resilience, while Software & Services emphasize recurring revenue models and the criticality of interoperability with laboratory information systems. Examining test type highlights varied clinical and commercial pathways: Carrier Testing and Diagnostic Testing often require deep clinical validation and payer engagement; New Born Screening and Prenatal Testing emphasize rapid turnaround and integration with public health infrastructure; Pharmacogenomics and Presymptomatic & Predictive Testing depend heavily on clinical guidelines and long‑term outcomes data; Preimplantation Testing presents unique regulatory and ethical considerations. By technology, Cytogenetics and Microarrays retain important roles for certain indications even as DNA Sequencing and PCR continue to expand; Gene Expression Profiling and sequencing-based approaches drive complex bioinformatics needs. Application-focused segmentation shows that Cancer and Genetic Disorders remain primary adoption areas due to clear clinical pathways, while Autoimmune Disorders, Chronic Diseases, and Neurodegenerative Diseases are emerging targets that require stronger biomarker validation. Distribution channel differences between Offline and Online pathways create varying customer engagement and compliance challenges, and end-user segmentation indicates that Diagnostic Laboratories, Home Settings, and Hospitals & Clinics each demand tailored product designs, service levels, and commercialization strategies. Synthesizing these perspectives enables more precise go-to-market planning, evidence generation prioritization, and investment choices aligned to where clinical utility, reimbursement, and operational feasibility intersect.
Regional perspective synthesizing divergent trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific with implications for adoption and investment
Regional dynamics shape adoption pathways, investment priorities, and operational realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, producing distinct opportunities and constraints for stakeholders.
In the Americas, robust private payer infrastructure and significant clinical research activity support rapid adoption of innovative tests, yet stakeholders also navigate fragmented reimbursement policies and concentrated purchasing power among large health systems. Transitioning to Europe, Middle East & Africa, mixed public and private funding models and diverse regulatory frameworks require nuanced market access strategies and local evidence generation. Emerging and established players in this region often prioritize partnerships with national laboratories and public health agencies to scale screening programs. Across Asia‑Pacific, rapid capacity building, government-led investment in genomic initiatives, and a growing diagnostic manufacturing base are driving increased local capability, while heterogeneity in regulatory pathways and payer systems necessitates differentiated launches and regional partnerships. Understanding these regional contrasts is essential for designing distribution models, locating manufacturing or R&D capacity, and prioritizing clinical indications that align with local health system priorities and reimbursement environments.
Competitive ecosystem assessment highlighting leading companies' strategic priorities, innovation pipelines, partnership models, and commercialization pathways
Competitive dynamics reflect a spectrum of capabilities from established diagnostics and instrument manufacturers to nimble innovators and service-oriented software providers, each pursuing differentiated strategies to capture clinical and commercial value.
Large, diversified companies leverage scale to integrate instrumentation, consumables, and service contracts, while platform specialists focus on improving throughput and reducing per-sample cost. Software and interpretation providers compete on the quality of variant calling, clinical annotation, and ease of integration with electronic health records. Meanwhile, emerging firms concentrate on narrow clinical niches, superior user experience for decentralized testing, or proprietary biomarkers that can command premium positioning. Across these archetypes, strategic priorities converge around partnerships for sample acquisition, collaborations with academic centers for evidence generation, and selective M&A to close capability gaps. Observed activity also includes increasing attention to reimbursement strategy, development of real-world evidence programs, and investment in regulatory affairs to accelerate clinical adoption. For decision-makers, understanding where competitors are making capability bets - whether in automated laboratory workflows, AI-enabled interpretation, or point-of-care and at-home testing - is central to defining competitive response and potential areas for collaboration or consolidation.
Actionable recommendations for industry leaders to optimize resilience, scale clinical utility, accelerate commercialization, and navigate regulatory and trade headwinds
Industry leaders should pursue a set of pragmatic, prioritized actions that enhance resilience, accelerate clinical impact, and strengthen commercial viability in a rapidly evolving ecosystem.
First, invest in supply chain resilience by diversifying suppliers, establishing regional sourcing options, and building flexible inventory strategies to absorb tariff and logistics shocks. Second, prioritize product portfolios toward indications and technologies with clear clinical utility and established reimbursement pathways, while maintaining selective investments in high‑potential emerging applications backed by rigorous evidence plans. Third, develop integrated value propositions that combine robust analytical performance with streamlined interpretation and clinician decision support, thereby reducing friction for adoption. Fourth, engage proactively with payers and regulators to shape evidence requirements, pursue value demonstration through pilot programs, and negotiate innovative reimbursement models where appropriate. Fifth, accelerate partnerships across the ecosystem - including academic centers, health systems, and technology firms - to share data, co-develop clinical studies, and scale implementation. Finally, strengthen data governance, privacy practices, and ethical frameworks to protect patients and build trust, particularly as testing expands into home settings and as data-sharing partnerships grow in complexity. Implementing these recommendations will require cross-functional alignment, clear KPIs, and scenario-based planning to balance near-term operational demands with longer-term strategic objectives.
Transparent research methodology outlining data sources, analytical frameworks, triangulation techniques, and validation processes used to ensure rigor and reliability
This research applies a mixed-methods approach that integrates primary stakeholder engagement with comprehensive secondary review and rigorous triangulation to ensure robust, decision-ready findings.
Primary inputs include structured interviews with clinical leaders, laboratory directors, payers, and commercial executives to capture first-hand perspectives on clinical utility, procurement behavior, and adoption barriers. Secondary analysis synthesizes peer-reviewed literature, regulatory guidance, technical white papers, and company disclosures to contextualize market-level trends and technology maturation. Data analysis employs cross-validation techniques, comparing thematic insights across sources to identify consistent signals while flagging areas of divergence that require additional validation. The segmentation framework was developed iteratively, mapping product, test type, technology, application, distribution channel, and end-user dimensions to stakeholder needs and regulatory contexts. Quality assurance steps included expert review sessions and scenario testing to assess the sensitivity of strategic conclusions to alternative assumptions. Limitations are acknowledged, including evolving regulatory landscapes and variable public reporting across jurisdictions, and the methodology emphasizes transparency about sources and reasoning so that readers can assess applicability to their specific operational context.
Conclusive synthesis that distills strategic insights, summarizes critical takeaways, and frames next steps for stakeholders operating within the genetic testing domain
The concluding synthesis distills strategic imperatives and highlights high‑leverage opportunities for organizations operating within the genetic testing arena, emphasizing agility, evidence excellence, and partnership-driven scale.
Key takeaways underscore that technological advancement alone will not guarantee success; rather, success depends on aligning analytic capability with clear clinical pathways, payer engagement, and operational readiness. Stakeholders that integrate robust interpretation software, establish trustworthy data governance, and cultivate payer and provider relationships will be best positioned to translate innovation into sustainable clinical use. Regional nuances and trade developments require tailored market access strategies and nimble supply chain planning, while a focus on end-user experience-whether in hospital laboratories or home settings-remains essential for adoption. Ultimately, companies that balance near‑term resilience with deliberate investment in evidence generation and interoperability will be able to capture long-term value and contribute meaningfully to improved patient outcomes.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction that frames the current genetic testing landscape, clarifies scope, and outlines strategic implications for stakeholders
This executive summary frames the contemporary genetic testing landscape by establishing the scope of analysis, clarifying core thematic drivers, and defining the strategic questions that matter most to stakeholders across healthcare, diagnostics, and life sciences industries.
The introduction situates genetic testing within a convergence of accelerating technological capability and shifting care models, highlighting how advances in sequencing, informatics, and decentralized testing are expanding diagnostic utility. It explains the analytic boundaries used in this study, including product categories, test modalities, technology platforms, clinical and nonclinical applications, distribution approaches, and end-user settings. By articulating these parameters, the section provides readers with a clear foundation for interpreting subsequent insights and for assessing how observed trends translate into operational and investment priorities. Finally, the introduction positions this work as a decision-oriented synthesis: it is designed to clarify implications for clinical adoption, commercialization, and policy engagement rather than to provide purely descriptive exposition.
Identification of transformative shifts reshaping genetic testing including technological advances, consumer behavior, regulatory dynamics, and care delivery models
The genetic testing landscape is undergoing a set of transformative shifts driven by technological maturation, evolving payer and regulatory frameworks, and changing patient expectations about access and control over health data.
On the technology front, improvements in throughput, accuracy, and cost-efficiency for next‑generation sequencing and complementary modalities are enabling broader clinical applications and accelerating translation from research to routine care. At the same time, software-driven interpretation, artificial intelligence, and cloud-based genomic informatics are redefining how results are processed and integrated into clinical workflows. From a regulatory and reimbursement standpoint, authorities and payers increasingly expect clear evidence of clinical utility and value, creating incentives for companies to generate real-world data and to engage early with health systems and payers. Consumer behavior is also shifting: greater health literacy and demand for convenience are expanding interest in at-home and direct-to-consumer testing pathways, while clinicians seek validated, action-oriented results that inform care decisions. Collectively, these shifts are pushing organizations to rethink product design, partnerships, and commercialization strategies, and they are raising the bar for evidence, interoperability, and data governance.
Assessment of cumulative effects stemming from United States tariff actions in 2025 on supply chains, pricing structures, global collaboration, and patient access
Recent tariff actions originating from the United States in 2025 introduce trade-related headwinds that compound existing supply chain fragilities for genetic testing stakeholders, from instrument manufacturers to clinical laboratories and hospital systems.
Tariffs on imported equipment and consumables can raise landed costs, prompting manufacturers and purchasers to reevaluate procurement strategies and inventory planning. As a consequence, laboratories may face compressed margins while also balancing the imperative to maintain uninterrupted testing capacity for patient care. In response, many organizations are accelerating supplier diversification, regional sourcing, and strategic stockpiling to mitigate near-term disruption. Over the medium term, tariffs can incentivize greater regional manufacturing investment and nearshoring of critical components, but such reconfiguration takes time and capital. These trade measures also influence global collaboration on research and development: partners may adjust contractual terms, timing of instrument deployments, and location of clinical studies to manage cost exposure. Importantly, tariff-induced cost increases risk uneven downstream effects on patient access, particularly for lower-income populations and for settings that lack robust procurement leverage. To preserve affordability and continuity of services, stakeholders will need to prioritize bilateral supplier agreements, engage proactively with trade and regulatory authorities, and model multiple scenarios to understand impacts across procurement, pricing, and reimbursement pathways.
Insightful segmentation analysis revealing how product, test type, technology, application, distribution channel, and end-user dynamics inform market positioning
A granular segmentation lens reveals differentiated dynamics across product, test type, technology, application, distribution channel, and end-user dimensions, each carrying distinct strategic implications.
When viewed by product, Consumables & Equipment experience capital expenditure sensitivities and logistics complexity that favor scale and supply resilience, while Software & Services emphasize recurring revenue models and the criticality of interoperability with laboratory information systems. Examining test type highlights varied clinical and commercial pathways: Carrier Testing and Diagnostic Testing often require deep clinical validation and payer engagement; New Born Screening and Prenatal Testing emphasize rapid turnaround and integration with public health infrastructure; Pharmacogenomics and Presymptomatic & Predictive Testing depend heavily on clinical guidelines and long‑term outcomes data; Preimplantation Testing presents unique regulatory and ethical considerations. By technology, Cytogenetics and Microarrays retain important roles for certain indications even as DNA Sequencing and PCR continue to expand; Gene Expression Profiling and sequencing-based approaches drive complex bioinformatics needs. Application-focused segmentation shows that Cancer and Genetic Disorders remain primary adoption areas due to clear clinical pathways, while Autoimmune Disorders, Chronic Diseases, and Neurodegenerative Diseases are emerging targets that require stronger biomarker validation. Distribution channel differences between Offline and Online pathways create varying customer engagement and compliance challenges, and end-user segmentation indicates that Diagnostic Laboratories, Home Settings, and Hospitals & Clinics each demand tailored product designs, service levels, and commercialization strategies. Synthesizing these perspectives enables more precise go-to-market planning, evidence generation prioritization, and investment choices aligned to where clinical utility, reimbursement, and operational feasibility intersect.
Regional perspective synthesizing divergent trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific with implications for adoption and investment
Regional dynamics shape adoption pathways, investment priorities, and operational realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, producing distinct opportunities and constraints for stakeholders.
In the Americas, robust private payer infrastructure and significant clinical research activity support rapid adoption of innovative tests, yet stakeholders also navigate fragmented reimbursement policies and concentrated purchasing power among large health systems. Transitioning to Europe, Middle East & Africa, mixed public and private funding models and diverse regulatory frameworks require nuanced market access strategies and local evidence generation. Emerging and established players in this region often prioritize partnerships with national laboratories and public health agencies to scale screening programs. Across Asia‑Pacific, rapid capacity building, government-led investment in genomic initiatives, and a growing diagnostic manufacturing base are driving increased local capability, while heterogeneity in regulatory pathways and payer systems necessitates differentiated launches and regional partnerships. Understanding these regional contrasts is essential for designing distribution models, locating manufacturing or R&D capacity, and prioritizing clinical indications that align with local health system priorities and reimbursement environments.
Competitive ecosystem assessment highlighting leading companies' strategic priorities, innovation pipelines, partnership models, and commercialization pathways
Competitive dynamics reflect a spectrum of capabilities from established diagnostics and instrument manufacturers to nimble innovators and service-oriented software providers, each pursuing differentiated strategies to capture clinical and commercial value.
Large, diversified companies leverage scale to integrate instrumentation, consumables, and service contracts, while platform specialists focus on improving throughput and reducing per-sample cost. Software and interpretation providers compete on the quality of variant calling, clinical annotation, and ease of integration with electronic health records. Meanwhile, emerging firms concentrate on narrow clinical niches, superior user experience for decentralized testing, or proprietary biomarkers that can command premium positioning. Across these archetypes, strategic priorities converge around partnerships for sample acquisition, collaborations with academic centers for evidence generation, and selective M&A to close capability gaps. Observed activity also includes increasing attention to reimbursement strategy, development of real-world evidence programs, and investment in regulatory affairs to accelerate clinical adoption. For decision-makers, understanding where competitors are making capability bets - whether in automated laboratory workflows, AI-enabled interpretation, or point-of-care and at-home testing - is central to defining competitive response and potential areas for collaboration or consolidation.
Actionable recommendations for industry leaders to optimize resilience, scale clinical utility, accelerate commercialization, and navigate regulatory and trade headwinds
Industry leaders should pursue a set of pragmatic, prioritized actions that enhance resilience, accelerate clinical impact, and strengthen commercial viability in a rapidly evolving ecosystem.
First, invest in supply chain resilience by diversifying suppliers, establishing regional sourcing options, and building flexible inventory strategies to absorb tariff and logistics shocks. Second, prioritize product portfolios toward indications and technologies with clear clinical utility and established reimbursement pathways, while maintaining selective investments in high‑potential emerging applications backed by rigorous evidence plans. Third, develop integrated value propositions that combine robust analytical performance with streamlined interpretation and clinician decision support, thereby reducing friction for adoption. Fourth, engage proactively with payers and regulators to shape evidence requirements, pursue value demonstration through pilot programs, and negotiate innovative reimbursement models where appropriate. Fifth, accelerate partnerships across the ecosystem - including academic centers, health systems, and technology firms - to share data, co-develop clinical studies, and scale implementation. Finally, strengthen data governance, privacy practices, and ethical frameworks to protect patients and build trust, particularly as testing expands into home settings and as data-sharing partnerships grow in complexity. Implementing these recommendations will require cross-functional alignment, clear KPIs, and scenario-based planning to balance near-term operational demands with longer-term strategic objectives.
Transparent research methodology outlining data sources, analytical frameworks, triangulation techniques, and validation processes used to ensure rigor and reliability
This research applies a mixed-methods approach that integrates primary stakeholder engagement with comprehensive secondary review and rigorous triangulation to ensure robust, decision-ready findings.
Primary inputs include structured interviews with clinical leaders, laboratory directors, payers, and commercial executives to capture first-hand perspectives on clinical utility, procurement behavior, and adoption barriers. Secondary analysis synthesizes peer-reviewed literature, regulatory guidance, technical white papers, and company disclosures to contextualize market-level trends and technology maturation. Data analysis employs cross-validation techniques, comparing thematic insights across sources to identify consistent signals while flagging areas of divergence that require additional validation. The segmentation framework was developed iteratively, mapping product, test type, technology, application, distribution channel, and end-user dimensions to stakeholder needs and regulatory contexts. Quality assurance steps included expert review sessions and scenario testing to assess the sensitivity of strategic conclusions to alternative assumptions. Limitations are acknowledged, including evolving regulatory landscapes and variable public reporting across jurisdictions, and the methodology emphasizes transparency about sources and reasoning so that readers can assess applicability to their specific operational context.
Conclusive synthesis that distills strategic insights, summarizes critical takeaways, and frames next steps for stakeholders operating within the genetic testing domain
The concluding synthesis distills strategic imperatives and highlights high‑leverage opportunities for organizations operating within the genetic testing arena, emphasizing agility, evidence excellence, and partnership-driven scale.
Key takeaways underscore that technological advancement alone will not guarantee success; rather, success depends on aligning analytic capability with clear clinical pathways, payer engagement, and operational readiness. Stakeholders that integrate robust interpretation software, establish trustworthy data governance, and cultivate payer and provider relationships will be best positioned to translate innovation into sustainable clinical use. Regional nuances and trade developments require tailored market access strategies and nimble supply chain planning, while a focus on end-user experience-whether in hospital laboratories or home settings-remains essential for adoption. Ultimately, companies that balance near‑term resilience with deliberate investment in evidence generation and interoperability will be able to capture long-term value and contribute meaningfully to improved patient outcomes.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing integration of artificial intelligence into genomic data interpretation workflows
- 5.2. Rising adoption of direct-to-consumer genetic test kits and associated regulatory oversight challenges
- 5.3. Advancements in CRISPR-based gene editing enabling precise targeting of hereditary disorders
- 5.4. Expansion of pharmacogenomics for personalized medication selection based on patient genetic profiles
- 5.5. Emergence of at-home sample collection kits improving access to genetic testing services in rural areas
- 5.6. Strategic partnerships between biotech firms and healthcare providers to scale genetic screening programs
- 5.7. Growing demand for comprehensive multiomics approaches integrating genomics proteomics and metabolomics data
- 5.8. Increasing venture capital investment driving innovation and startup growth in the genetic testing sector
- 5.9. Evolving regulatory frameworks and data privacy requirements impacting genetic testing commercialization strategies
- 5.10. Surge in prenatal genetic screening as expectant parents seek early detection of hereditary health risks
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Genetic Testing Market, by Product
- 8.1. Consumables & Equipment
- 8.2. Software & Services
- 9. Genetic Testing Market, by Test Type
- 9.1. Carrier Testing
- 9.2. Diagnostic Testing
- 9.3. New Born Screening
- 9.4. Pharmacogenomics
- 9.5. Preimplantation Testing
- 9.6. Prenatal Testing
- 9.7. Presymptomatic & Predictive Testing
- 10. Genetic Testing Market, by Technology
- 10.1. Cytogenetics
- 10.2. DNA Sequencing
- 10.3. Gene Expression Profiling
- 10.4. Microarrays
- 10.5. PCR
- 11. Genetic Testing Market, by Application
- 11.1. Autoimmune Disorders
- 11.2. Cancer
- 11.3. Chronic Diseases
- 11.4. Genetic Disorders
- 11.5. Neurodegenerative Diseases
- 12. Genetic Testing Market, by Distribution Channel
- 12.1. Offline
- 12.2. Online
- 13. Genetic Testing Market, by End-User
- 13.1. Diagnostic Laboratories
- 13.2. Home Setting
- 13.3. Hospitals & Clinics
- 14. Genetic Testing Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Genetic Testing Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Genetic Testing Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abbott Laboratories
- 17.3.2. Agilent Technologies, Inc.
- 17.3.3. Becton, Dickinson and Company
- 17.3.4. Bio-Rad Laboratories, Inc.
- 17.3.5. Bio-Techne Corporation
- 17.3.6. Bruker Corporation
- 17.3.7. Centogene N.V.
- 17.3.8. Color Health, Inc.
- 17.3.9. CooperSurgical Inc.
- 17.3.10. Editas Medicine, Inc.
- 17.3.11. Eugene Labs Pty Ltd.
- 17.3.12. Eurofins Scientific SE
- 17.3.13. F. Hoffmann-La Roche AG
- 17.3.14. Fulgent Genetics, Inc.
- 17.3.15. Gene by Gene, Ltd.
- 17.3.16. GeneDx, LLC
- 17.3.17. Illumina, Inc.
- 17.3.18. Invitae Corporation
- 17.3.19. Laboratory Corporation of America Holdings
- 17.3.20. Living DNA Ltd.
- 17.3.21. Macrogen, Inc.
- 17.3.22. MyHeritage Ltd.
- 17.3.23. Myriad Genetics, Inc.
- 17.3.24. Natera, Inc.
- 17.3.25. Newtopia Inc.
- 17.3.26. PathogenDx Corporation
- 17.3.27. PerkinElmer Inc.
- 17.3.28. Qiagen N.V.
- 17.3.29. Quest Diagnostics Incorporated
- 17.3.30. Sanofi S.A.
- 17.3.31. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
